Stocks Health care NVS
NYSE · Health careNovartis AG (NVS)
Operating cash flow minus capital spending left $17.6B of free cash flow in fiscal 2025. At December 31, 2025 it held $11.4B in cash against $28.7B of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on February 4, 2026.
What Novartis AG does
Novartis discovers, develops, and manufactures prescription pharmaceuticals and gene therapies. It sells medications directly to healthcare providers, hospitals, and pharmacies globally. The company is known for treatments in oncology, immunology, cardiology, and neuroscience. Its shares trade on NYSE under the ticker NVS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | $14B | $7.15 | $17.6B |
| 2024 | n/a | $11.9B | $5.87 | $16.3B |
| 2023 | n/a | $14.9B | $7.10 | $13.4B |
| 2022 | n/a | $7B | $3.17 | $13.3B |
| 2021 | n/a | $24B | $10.63 | $14B |
| 2020 | n/a | $8.1B | $3.52 | $12.4B |
Full financial statements: income, balance sheet and cash flow
Dividends
It paid out $7.8B in cash dividends, 56% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | n/a | $7.8B | 56% |
| 2024 | n/a | $7.6B | 64% |
| 2023 | n/a | $7.3B | 49% |
| 2022 | n/a | $7.5B | 108% |
| 2021 | n/a | $7.4B | 31% |
| 2020 | n/a | $7B | 87% |
Latest SEC filings
What Novartis AG has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 8, 2026
- September 4, 2026
- September 1, 2026
- July 21, 2026
- June 11, 2026
- April 28, 2026
- March 18, 2026
- March 17, 2026
- March 17, 2026
- March 16, 2026
Who owns NVS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC13G, passive | 6.4% | July 17, 2025 |
Largest institutional holders
Insiders
Questions about NVS
What does Novartis AG do?
Novartis discovers, develops, and manufactures prescription pharmaceuticals and gene therapies. It sells medications directly to healthcare providers, hospitals, and pharmacies globally. The company is known for treatments in oncology, immunology, cardiology, and neuroscience. Its shares trade on NYSE under the ticker NVS.
Is Novartis AG profitable?
Yes. In fiscal 2025 it reported net income of $14B.
When did Novartis AG last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on February 4, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 8, 2026.
Similar companies
Compare NVS with
Follow NVS
Get an email when Novartis AG files with the SEC: results, executive changes, material agreements and annual reports.
Follow NVS: get an email when it filesWhere the numbers come from
Financial figures are the values Novartis AG tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.